CRTC2 and neoplasm: Recently, co-treatment with an ATP competitive, dual TORC1 and TORC2 inhibitor was shown to enhance the pre-clinical anti-tumor efficacy of a pan-HDAC inhibitor against primary xenograft models of hepatocellular carcinoma [38].